Core Insights - Kintor Pharmaceutical (02171.HK) announced clinical data for its universal BCMA CAR-T product CT0596 and universal CD19/CD20 CAR-T product CT1190B, both showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin lymphoma (R/R NHL) respectively [1][2] Group 1: Product Development - CT0596 is a universal CAR-T cell therapy targeting BCMA, currently undergoing investigator-initiated clinical trials for R/R MM and plasma cell leukemia (PCL), with plans to submit an IND application in the second half of 2025 [1] - CT1190B targets CD19/CD20 and is involved in clinical trials for treating relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc) [2] Group 2: Company Overview - Kintor Pharmaceutical is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [2] - The company has established end-to-end capabilities in CAR-T cell research and development, from target discovery to commercial-scale production, positioning itself as a leading global player in CAR-T therapy [2] - Kintor currently has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [2]
科济药业公布通用型CAR-T产品积极临床数据